Skip to Content

What type of drug is Lorbrena?

Medically reviewed by Last updated on Dec 1, 2020.

What condition is it used to treat?

Official Answer


Lorbrena is an anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor (TKI).

Lorbrena (lorlatinib) was approved in November 2018 for the treatment of patients with ALK-positive metastatic non-small cell lung cancer (NSCLC) whose disease has progressed on other ALK TKIs.

Lorbrena is a new option for NSCLC patients who have progressed but provides an option to remain on oral therapy. The recommended dosage is 100 mg orally once daily.

Other ALK tyrosine kinase inhibitors include:

Related Medical Questions

Drug Information

Related Support Groups